Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Palatin and US Army work on inhaled anthrax test:

This article was originally published in Clinica

Executive Summary

Palatin Technologies has teamed-up with the US Army to evaluate the firm's radiolabelled imaging agent, LeuTech, for early detection of inhaled anthrax infection. A study enrolling up to 500 individuals at potential risk of inhaling anthrax spores was to begin last week at the Walter Reed Army Medical Center, Washington. LeuTech is a monoclonal antibody that binds to white bloods cells, which collect at infection sites, enabling the infection to be detected easily and rapidly using a gamma camera (see this issue, p 9).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT074018

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel